Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged \>/=18 years~* Adequate bone marrow, liver, and renal functions~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Diseases as defined below:~PART1~* Subjects with CLL with either del(17p) by FISH or TP53 mutation who have received ≥1 prior therap(ies) and the last prior regimen must have included venetoclax plus an anti-CD20 antibody and/or a BTKi and did not produce complete remission. Subjects with CLL with either del(17p) by FISH or TP53 mutation who have received ≥2 prior regimens and are intolerant to BTKi and/or venetoclax are also eligible.~or~* Subjects with CLL transformed to DLBCL who have relapsed after, or been refractory, to at least 1 prior line of therapy for DLBCL~PART2~* Subjects with CLL who are currently on an approved BTKi (monotherapy only) at the dose and schedule per the local label for ≥ 12 months who have only achieved SD, PR or PRL~Exclusion Criteria:~* Active clinically serious infections of Grade \> 2; requiring parenteral therapy~* Subjects who have new or progressive brain or meningeal or spinal metastases.~* Anticancer chemotherapy or immunotherapy during the study or within one week prior to the first dose of study drug~* Major surgery or significant trauma within 4 weeks before the first dose of study drug~* Allogeneic bone marrow transplant or stem cell rescue within 4 months before first dose of study drug; patients must have completed immunosuppressive therapy before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monotherapy of VIP152 (Type: EXPERIMENTAL): Investigating VIP152 in a monotherapy cohort in patients with high-risk CLL and Richter Syndrome
- VIP152 in combination with BTKi (Type: EXPERIMENTAL): Investigating VIP152 in combination with a BTKi in patients with CLL

Based on this trial design, predict the completion outcome and termination type (if applicable).